JP2019524701A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019524701A5 JP2019524701A5 JP2019500245A JP2019500245A JP2019524701A5 JP 2019524701 A5 JP2019524701 A5 JP 2019524701A5 JP 2019500245 A JP2019500245 A JP 2019500245A JP 2019500245 A JP2019500245 A JP 2019500245A JP 2019524701 A5 JP2019524701 A5 JP 2019524701A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chain variable
- variable region
- antagonist
- set forth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662359073P | 2016-07-06 | 2016-07-06 | |
| US62/359,073 | 2016-07-06 | ||
| PCT/US2017/040665 WO2018009507A1 (en) | 2016-07-06 | 2017-07-05 | Combination of tim-4 antagonist and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019524701A JP2019524701A (ja) | 2019-09-05 |
| JP2019524701A5 true JP2019524701A5 (enExample) | 2020-08-13 |
| JP7164512B2 JP7164512B2 (ja) | 2022-11-01 |
Family
ID=59366515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019500245A Active JP7164512B2 (ja) | 2016-07-06 | 2017-07-05 | Ｔｉｍ－４アンタゴニストとｐｄ－１アンタゴニストの組合せおよび使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11306143B2 (enExample) |
| EP (1) | EP3481866B1 (enExample) |
| JP (1) | JP7164512B2 (enExample) |
| KR (1) | KR102602137B1 (enExample) |
| CN (1) | CN109641968B (enExample) |
| ES (1) | ES2992868T3 (enExample) |
| WO (1) | WO2018009507A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA019344B1 (ru) * | 2005-07-01 | 2014-03-31 | МЕДАРЕКС, Эл.Эл.Си. | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения |
| EP3481866B1 (en) | 2016-07-06 | 2024-07-24 | Bristol-Myers Squibb Company | Combination of tim-4 antagonist and pd-1 antagonist and methods of use |
| WO2021064184A1 (en) * | 2019-10-04 | 2021-04-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer |
| CN110982824B (zh) * | 2019-10-09 | 2022-04-15 | 天津大学 | 拮抗pd-1的抗体类似物bp基因及蛋白和应用 |
| US11774451B2 (en) * | 2019-11-21 | 2023-10-03 | The Board Of Trustees Of The Leland Stanford Junior University | Molecular vibrational spectroscopic markers for detection of cancer |
| WO2022165511A1 (en) * | 2021-01-29 | 2022-08-04 | Lapix Therapeutics, Inc. | Tartaric acid analogs and uses thereof |
| WO2023019137A1 (en) * | 2021-08-10 | 2023-02-16 | Heat Biologics, Inc. | Generation and characterization of novel tim-4 binding agents |
| US11648225B2 (en) | 2021-08-13 | 2023-05-16 | Lapix Therapeutics, Inc. | Compositions and methods for reducing immune intolerance and treating autoimmune disorders |
| CN115957304A (zh) * | 2022-10-18 | 2023-04-14 | 山东大学 | Tim-4调控胆固醇合成中的应用 |
| AU2024207355A1 (en) * | 2023-01-13 | 2025-08-21 | Chimagen Biosciences, Ltd | Multi-specific polypeptide complexes |
| WO2025077833A1 (en) * | 2023-10-11 | 2025-04-17 | Suzhou Neologics Bioscience Co., Ltd. | Antibodies targeting tim-3 and pd-1 and uses thereof |
| CN117904122B (zh) * | 2023-12-22 | 2025-01-28 | 北京贝来药业有限公司 | 一种编码抗pd-1抗体的基因及其修饰干细胞的制备和应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
| KR900005995A (ko) | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | 변형 인터류킨-2 및 그의 제조방법 |
| US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
| WO1991006570A1 (en) | 1989-10-25 | 1991-05-16 | The University Of Melbourne | HYBRID Fc RECEPTOR MOLECULES |
| US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
| DE69123241T2 (de) | 1990-12-14 | 1997-04-17 | Cell Genesys Inc | Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
| CA2196200A1 (en) | 1994-07-29 | 1996-02-15 | Michael Joseph Browne | Novel compounds |
| TW200539890A (en) | 2004-03-12 | 2005-12-16 | Brigham & Womens Hospital | Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function |
| CN101035561A (zh) * | 2004-03-24 | 2007-09-12 | 特罗斯药品公司 | 作为改善对疫苗的免疫反应的佐剂的组合物和使用方法 |
| ES2720160T3 (es) | 2005-05-09 | 2019-07-18 | Ono Pharmaceutical Co | Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas |
| EA019344B1 (ru) | 2005-07-01 | 2014-03-31 | МЕДАРЕКС, Эл.Эл.Си. | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения |
| US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
| JP2015209376A (ja) | 2014-04-24 | 2015-11-24 | 国立大学法人北海道大学 | 腫瘍特異的免疫増強剤 |
| EP3481866B1 (en) | 2016-07-06 | 2024-07-24 | Bristol-Myers Squibb Company | Combination of tim-4 antagonist and pd-1 antagonist and methods of use |
-
2017
- 2017-07-05 EP EP17740851.5A patent/EP3481866B1/en active Active
- 2017-07-05 WO PCT/US2017/040665 patent/WO2018009507A1/en not_active Ceased
- 2017-07-05 KR KR1020197003493A patent/KR102602137B1/ko active Active
- 2017-07-05 JP JP2019500245A patent/JP7164512B2/ja active Active
- 2017-07-05 CN CN201780054101.9A patent/CN109641968B/zh active Active
- 2017-07-05 ES ES17740851T patent/ES2992868T3/es active Active
- 2017-07-05 US US16/314,732 patent/US11306143B2/en active Active
-
2022
- 2022-03-14 US US17/693,975 patent/US12227575B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019524701A5 (enExample) | ||
| JP2016537383A5 (enExample) | ||
| JP2020055853A5 (enExample) | ||
| JP2019510733A5 (enExample) | ||
| JP2017524715A5 (enExample) | ||
| JP2020502271A5 (enExample) | ||
| JP2017535257A5 (enExample) | ||
| JP2017048240A5 (enExample) | ||
| IL253462B (en) | Cancer treatment with monoclonal antibodies against latency-associated peptide | |
| JP2018523493A5 (enExample) | ||
| HRP20210440T1 (hr) | Kombinirana terapija za rak | |
| JP2018532383A5 (enExample) | ||
| JP2019110906A5 (enExample) | ||
| JP2018536632A5 (ja) | Ｂ７‐ｈ３に特異的に結合する分子及びｐｄ‐１に特異的に結合する分子 | |
| PH12020551173A1 (en) | Anti-pd-l1 antibodies and uses thereof | |
| JP2017500057A5 (enExample) | ||
| RU2016124540A (ru) | Композиции, содержащие анти-сеасам 1 и анти-pd антитела для терапии рака | |
| JP2018508483A5 (enExample) | ||
| JP2020514310A5 (enExample) | ||
| JP2016533763A5 (ja) | ヒトｐｄ−１に特異的に結合する抗体抗原結合ドメインおよびそれを含む医薬組成物 | |
| JP2014522850A5 (enExample) | ||
| JP2015535828A5 (enExample) | ||
| JP2018516911A5 (enExample) | ||
| JP2017513900A5 (enExample) | ||
| JP2015532292A5 (enExample) |